Navigation Links
Nutrition 21 Appoints Pam McWilliams, Vice President - General Manager of Direct Response

PURCHASE, N.Y., Oct. 30 /PRNewswire-FirstCall/ -- Nutrition 21, Inc., (Nasdaq: NXXI) today announced the appointment of Pam McWilliams as vice president and general manager of the Company's Direct Response Group, effective October 27, 2008. Mrs. McWilliams has more than 22 years of experience in sales, marketing, management and business development within the direct response industry. Mrs. McWilliams' responsibilities include new business development, sales strategy, vendor operations and management of the Direct Response Group.

Mrs. McWilliams will be based out of Nutrition 21's headquarters in Purchase, NY and will report to Michael A. Zeher, president and CEO of Nutrition 21, who said, "I am very pleased that Pam McWilliams is joining the Nutrition 21 management team. Her excellent experience, broad background, and relationships in the direct response industry will be valuable assets to our company. I am looking forward to the combination of Pam's leadership skills, high integrity, and business acumen being an energizing force in leading Nutrition's 21's Direct Response Group to even higher levels of performance."

"I am extremely pleased to join the leadership team at Nutrition 21," said Mrs. McWilliams. The value the company places on integrity, industry leadership, and supporting high quality brands in the bioscience industry is what attracted me to Nutrition 21. These values create an exciting opportunity to differentiate Nutrition 21 from its competitors, increase market share, and achieve unprecedented levels of customer satisfaction and long term brand loyalty. By drawing from my professional experience and collaborating with the leadership team, Nutrition 21 will continue to implement a direct marketing strategy to deliver cutting edge, high quality nutritional supplements with a demonstrated commitment towards best-in-class customer service."

For the past two years Mrs. McWilliams was a direct marketing consultant for Propeller Consulting. Prior to that Mrs. McWilliams served for 21 years at Bee Alive, Inc., a direct marketing health and beauty company, most recently as executive vice president. Beginning as a three-person operation, Mrs. McWilliams helped grow the Bee Alive organization to 150 employees while achieving millions in annual sales. Mrs. McWilliams' responsibilities included management and business development, return on investment (ROI) analysis, marketing and promotion, product development, profit and loss (P&L), expense management, and systems implementation.

About Nutrition 21

Nutrition 21, Inc. (NASDAQ: NXXI), headquartered in Purchase, NY, is a nutritional bioscience company and the maker of chromium picolinate-based and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. Nutrition 21 holds more than 30 patents for nutrition products and uses. Nutrition 21's portfolio of health and wellness products include: Iceland Health Chromax(R), Iceland Health Advanced Memory Formula(TM), Diabetes Essentials(R), Iceland Health(R) Maximum Strength Omega-3 and Iceland Health(R) Joint Relief. The company also manufactures private label supplements and ingredients for third parties. Nutrition 21 distributes its products nationally through more than 29,000 major food, drug and super center stores throughout the United States and internationally. For more information please visit

Safe Harbor Provision

This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the Company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including its Form 10-K/A for the year ended June 30, 2008. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.

Company Contact: Investor Contact:

Alan Kirschbaum Lytham Partners, LLC

Chief Financial Officer Joe Diaz, Joe Dorame, Robert Blum

914-701-4500 602-889-9700

SOURCE Nutrition 21, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Company to Develop Nutritional Interventions Against Chronic Inflammatory and Infectious Diseases
2. GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
3. Neptune Technologies and Marine Life Sciences enter worldwide distribution alliance with Weider Global Nutrition
4. Nano-sized trojan horse to aid nutrition
5. iNutrition Launches New Fission Fruit Nutrition Bars
6. Galaxy Nutritional Foods Reports FY2008 Results
7. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
8. Better Nutrition Launches 2008 Summer Nutrition Tour
9. SURGEX(TM) Becomes the Official Sports Nutrition Drink of Former NBA Player Dee Brown and his Edge Basketball Training Facility
10. Tom Shaws NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen
11. Nutrition 21 to Report Second Quarter Fiscal 2008 Financial Results Monday, February 11, 2008
Post Your Comments:
(Date:11/28/2015)... ... ... • Jeon Jin Bio Corp, a Korean Biotech venture company, has developed ... Bird Free, an oil-based, gel formula made from natural ... smell, taste and touch, enabling safe, effective avian control without toxic chemicals , ...
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
Breaking Biology Technology:
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):